We advised the joint book-running managers and representatives of the several underwriters

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $60 million units offering by Tenaya Therapeutics, Inc. The offering consisted of 50 million units to purchase one share of common stock and warrants.

Based in South San Francisco, California, Tenaya is a clinical-stage biotechnology company focused on discovering, developing and delivering potentially curative therapies to address the underlying drivers of heart disease. Tenaya’s vision is to change the treatment paradigm for heart disease, and in doing so improve and extend the lives of millions of patients. Tenaya’s common stock is listed on the Nasdaq Global Select Market under the symbol “TNYA.”

The Davis Polk corporate team included partners Alan F. Denenberg and Emily Roberts and associates Savannah J. Dowling, Jared Madnick and Matthew Kenney. Partner David R. Bauer and associate Gabrielle Mazero provided intellectual property advice. The tax team included counsel Dustin Plotnick and associate Nancy B. Regan. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post